Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxone prolonged-release pharmacokinetic study in children with opioid-induced constipation
2015-002310-72Phase 2Suspended
- Sponsor
- Develco Pharma
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of naloxone in opioid-induced constipation (OIC), sponsored by Develco Pharma. Primary endpoint: Pharmacokinetic parameters of naloxone-3-glucuronide. Started Dec 2015; status: suspended.
02
Drugs
naloxone
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on 2015-002310-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002310-72.